[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6033 Introduced in House (IH)]
112th CONGRESS
2d Session
H. R. 6033
To provide for research and education to improve screening, detection
and diagnosis of prostate cancer.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 27, 2012
Mr. Cummings (for himself, Mr. Burton of Indiana, Mr. Carson of
Indiana, Mrs. Christensen, Ms. Clarke of New York, Mr. Clay, Mr.
Jackson of Illinois, and Mr. Rangel) introduced the following bill;
which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To provide for research and education to improve screening, detection
and diagnosis of prostate cancer.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Prostate Cancer Detection Research
and Education Act''.
SEC. 2. PLAN TO DEVELOP AND VALIDATE A TEST OR TESTS FOR PROSTATE
CANCER.
(a) In General.--The Secretary of Health and Human Services
(referred to in this Act as the ``Secretary''), acting through the
Director of the National Institutes of Health, shall establish an
advisory council on prostate cancer (referred to in this Act as the
``advisory council'') to draft a plan for the development and
validation of an accurate test or tests, such as biomarkers or imaging,
to detect and diagnose prostate cancer.
(b) Advisory Council.--
(1) Membership.--
(A) Federal members.--The advisory council shall be
comprised of the following experts:
(i) A designee of the Centers for Disease
Control and Prevention.
(ii) A designee of the Centers for Medicare
& Medicaid Services.
(iii) A designee of the Office of the
Director of the National Cancer Institute.
(iv) A designee of the Director of the
Department of Defense Congressionally Directed
Medical Research Program.
(v) A designee of the Director of the
National Institute of Biomedical Imaging and
Bioengineering.
(vi) A designee of the Director of the
National Institute of General Medical Sciences.
(vii) A designee of the Director of the
National Institute on Minority Health and
Health Disparities.
(viii) A designee of the Office of the
Director of the National Institutes of Health.
(ix) A designee of the Food and Drug
Administration.
(x) A designee of the Agency for Healthcare
Research and Quality.
(xi) A designee of the Director of the
Telemedicine and Advanced Technology Research
Center of the Department of Defense.
(B) Non-federal members.--In addition to the
members described in subparagraph (A), the advisory
council shall include 8 expert members from outside the
Federal Government to be appointed by the Secretary,
which shall include--
(i) 2 prostate cancer patient advocates;
(ii) 2 health care providers with a range
of expertise and experience in prostate cancer;
and
(iii) 4 leading researchers with prostate
cancer-related expertise in a range of clinical
disciplines.
(2) Meetings.--The advisory council shall meet quarterly
and such meetings shall be open to the public.
(3) Advice.--The advisory council shall advise the
Secretary, or the Secretary's designee.
(4) Annual report.--Not later than 1 year after the date of
enactment of this Act, the advisory council shall provide to
the Secretary, or the Secretary's designee and Congress--
(A) an initial evaluation of all federally funded
efforts in prostate cancer research relating to the
development and validation of an accurate test or tests
to detect and diagnose prostate cancer;
(B) a plan for the development and validation of a
reliable test or tests for the detection and accurate
diagnosis of prostate cancer; and
(C) a set of standards for prostate cancer
screening, developed in coordination with the United
States Preventive Services Task Force, to ensure that
any tools for screening, detection, and diagnosis
developed in accordance with the plan under
subparagraph (B) will meet the requirements of the Task
Force for recommendation as a proven preventive or
diagnostic service.
(5) Termination.--The advisory council shall terminate on
December 31, 2016.
(c) Funding.--The Secretary may make available $1,000,000 from
amounts appropriated to the National Institutes of Health for each of
fiscal years 2013 through 2017 to carry out this section.
SEC. 3. COORDINATION AND INTENSIFICATION OF PROSTATE CANCER RESEARCH.
(a) In General.--The Director of the National Institutes of Health,
in consultation with the Secretary of Defense, shall coordinate and
intensify research in accordance with the plan developed under section
2(b)(4)(B), with particular attention provided to leveraging existing
research to develop and validate a test or tests, such as biomarkers or
imaging, to detect and accurately diagnose prostate cancer in order to
improve quality of life for millions of Americans, and decrease health
care system costs.
(b) Funding.--The Secretary may make available $30,000,000 from
amounts appropriated to the National Institutes of Health for each of
fiscal years 2014 through 2018 to carry out this section.
SEC. 4. PUBLIC AWARENESS AND EDUCATION CAMPAIGN.
(a) National Campaign.--The Secretary, in coordination with the
Director of the National Institutes of Health and the Director of the
Centers for Disease Control and Prevention, shall carry out a national
campaign to increase the awareness and knowledge of prostate cancer.
(b) Requirements.--The national campaign conducted under subsection
(a) shall include--
(1) roles for the National Cancer Institute, the National
Institute on Minority Health and Health Disparities, the Office
on Minority Health of the Department of Health and Human
Services, and the Office of Minority Health of the Centers for
Disease Control and Prevention; and
(2) the development and distribution of written educational
materials, and the development and placing of public service
announcements, that are intended to encourage men to seek
prostate cancer screening when symptoms are present, when they
have a family history of prostate cancer, or if they belong to
a high-risk population.
(c) Racial Disparities.--In developing the national campaign under
subsection (a), the Secretary shall recognize and address--
(1) the racial disparities in the incidences of prostate
cancer and mortality rates with respect to such disease; and
(2) any barriers in access to patient care and
participation in clinical trials that are specific to racial
minorities.
(d) Grants.--The Secretary shall establish a program to award
grants to nonprofit private entities to enable such entities to test
alternative outreach and education strategies to increase the awareness
and knowledge of Americans with respect to prostate cancer.
(e) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section, $5,000,000 for each of fiscal
years 2013 through 2017.
<all>